Company intelligence / Profile preview

20Med Therapeutics

Enschede, Overijssel, Netherlands20medtx.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Positive preclinical results have been published for an mRNA influenza vaccine using the proprietary polymeric nanoparticle technology. The data demonstrate strong protective effects and efficient intracellular delivery of genetic material. Clinical trials have not yet commenced.

Therapeutic areas: Rare DiseasesOncologyInfectious Diseases
Modalities: mRNA-based drugsDNA vaccineSmall interfering RNA (siRNA)MicroRNA therapy (miRNA)Nanoparticle
Industry: Biotech

Partnerships

Not specifically named; company actively seeking partners at industry events such as BIO International Convention.

Beyond the preview

Go deeper on 20Med Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20Med Therapeutics.

Explore the full profile